
|Articles|February 1, 2003
Melanoma Revision
New York - Researchers have identified a molecular biomarker that was shown in a study to predict survival in melanoma patients, independently of tumor thickness and other known prognostic indicators.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
5


















